Aardvark Therapeutics, Inc. (NASDAQ:AARD)
| Market Cap | $20.20M-90.3% |
| Revenue (ttm) | $0 |
| Net Income | -$72.76M-49.2% |
| EPS | -$3.34-49.1% |
| Shares Out | 21.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 241,067 |
| Open | $1.00 |
| Previous Close | $1.00 |
| Day's Range | $0.90 - $1.04 |
| 52-Week Range | $0.90 - $16.60 |
| Beta | 3.81 |
| Analysts | Buy |
| Price Target | $2.40(+160.13%) |
| Earnings Date | Mar 22, 2027 |
About AARD
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating AARD in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 22, 2027Earnings report
$AARD stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AARD holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AARD's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AARD Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AARD Revenue by Segment
| Facilities-related and other allocated costs | $215.00K | 96.41% |
| Unrealized (gains) losses on short-term investments | $8.00K | 3.59% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AARD patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AARD from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AARD
| VTIVanguard Morningstar Total Stock Market ETF | $417.75K |
| VXFVanguard Extended Market ETF | $190.93K |
| IBBiShares Biotechnology ETF | $90.21K |
| IWCiShares Micro-Cap ETF | $35.18K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $20.00K |
| DXUVU.S. Vector Equity Portfolio ETF Class Shares | $2.24K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from AARD’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 12Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
